Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM

MASRI, A orcid iconORCID: 0000-0002-6390-6526, SHERRID, MV, CHOUDHURY, L, GARCIA-PAVIA, P, KRAMER, CM, BARRIALES-VILLA, R, COOPER, RM orcid iconORCID: 0000-0001-7482-828X, ELLIOTT, PM, HEGDE, SM, MARON, MS, NASSIF, ME, Oreziak, A, OWENS, AT, SOLOMON, SD, TOWER-RADER, A, HEITNER, SB, JACOBY, DL, KUPFER, S, MALIK, FI, MELLONI, C et al (2025) Safety and Efficacy of Aficamten in Patients With Nonobstructive Hypertrophic Cardiomyopathy: A 96-Week Analysis From FOREST-HCM. Journal of Cardiac Failure. ISSN 1071-9164

[thumbnail of 1-s2.0-S1071916425004312-main.pdf]
Preview
Text
1-s2.0-S1071916425004312-main.pdf - Accepted Version
Available under License Creative Commons Attribution.

Download (617kB) | Preview
Open Access URL: https://doi.org/10.1016/j.cardfail.2025.09.016 (Accepted version)
Item Type: Article
Uncontrolled Keywords: FOREST-HCM Investigators; aficamten; clinical trial; non-obstructive hypertrophic cardiomyopathy; patient-reported outcomes; 32 Biomedical and Clinical Sciences; 3201 Cardiovascular Medicine and Haematology; 3202 Clinical Sciences; Heart Disease; Cardiovascular; Rare Diseases; Pediatric; Patient Safety; Congenital Heart Disease; Pediatric Cardiomyopathy; Cardiovascular; 1102 Cardiorespiratory Medicine and Haematology; 1103 Clinical Sciences; 1110 Nursing; Cardiovascular System & Hematology; 3201 Cardiovascular medicine and haematology; 3202 Clinical sciences
Subjects: R Medicine > RC Internal medicine > RC1200 Sports Medicine
Divisions: Sport and Exercise Sciences
Publisher: Elsevier BV
Date of acceptance: 6 September 2025
Date of first compliant Open Access: 14 January 2026
Date Deposited: 14 Jan 2026 11:57
Last Modified: 14 Jan 2026 11:57
DOI or ID number: 10.1016/j.cardfail.2025.09.016
URI: https://researchonline.ljmu.ac.uk/id/eprint/27908
View Item View Item